Manipulation of acute inflammatory lung disease

Mucosal Immunology

Volumn 1, Issue 4, 2008, Pages 265-278

  Wissinger, E L ^a   Saldana, J ^a   Didierlaurent, A ^a,b   Hussell, T ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIOXIDANT; BUTYLATED HYDROXYANISOLE; CASPASE 9 INHIBITOR; CASPASE INHIBITOR; CHEMOKINE RECEPTOR; EFALIZUMAB; FINGOLIMOD; FUNGAL POLYSACCHARIDE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 10; LACTOBACILLUS CASEI EXTRACT; LEFLUNOMIDE; LYMPHOTOXIN; MANGANESE SUPEROXIDE DISMUTASE; METHIONINE RANTES; NATALIZUMAB; NITRIC OXIDE; PEGINTERFERON ALPHA; POLYSACCHARIDE; PORPHYRIN DERIVATIVE; RANTES; RECOMBINANT ALPHA INTERFERON; RESVERATROL; RETINOIC ACID; RIBAVIRIN; SPHINGOSINE 1 PHOSPHATE; STEROID; TERIFLUNOMIDE;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACTERIAL PNEUMONIA; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL TRIAL; CROHN DISEASE; DRUG MECHANISM; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; INFLUENZA; INNATE IMMUNITY; LUNG PARENCHYMA; LYMPHOCYTE MIGRATION; LYMPHOID TISSUE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOSE MUCOSA; OXIDATIVE STRESS; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECEPTOR BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; REVIEW; SEPTICEMIA; SERRATIA MARCESCENS; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS PNEUMONIA;

EID: 45449092825     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.16     Document Type: Review

References (217)

1. Bienenstock, J. & McDermott, M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol. Rev. 206, 22-31 (2005).
2. Debertin, A.S. et al. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin. Exp. Immunol. 134, 503-507 (2003).
3. Kuper, C.F. et al. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13, 219-224 (1992).
4. Rangel-Moreno, J., Moyron-Quiroz, J.E., Hartson, L., Kusser, K. & Randall, T.D. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl. Acad. Sci. USA 104, 10577-10582 (2007).
5. Pabst, R. Is BALT a major component of the human lung immune system? Immunol. Today 13, 119-122 (1992).
6. Xu, B. et al. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/ VCAM-1, and LFA-1 adhesion pathways. J. Exp. Med. 197, 1255-1267 (2003).
7. Moyron-Ouiroz, J.E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10 927-934 (2004).
8. Zuercher, A.W. & Cebra, J.J. Structural and functional differences between putative mucosal inductive sites of the rat. Eur. J. Immunol. 32, 3191-3196 (2002).
9. Marquez, M.G., Sosa, G.A. & Roux, M.E. Developmental study of immunocompetent cells in the bronchus-associated lymphoid tissue (BALT) from Wistar rats. Dev. Comp. Immunol. 24, 683-689 (2000).
10. Tschernig, T., Kleemann, W.J. & Pabst, R. Bronchus-associated lymphoid tissue (BALT) in the lungs of children who had died from sudden infant death syndrome and other causes. Thorax 50, 658-660 (1995).
11. Hiller, A.S., Tschernig, T., Kleemann, W.J. & Pabst, R. Bronchus-associated lymphoid tissue (BALT) and larynx-associated lymphoid tissue (LALT) are found at different frequencies in children, adolescents and adults. Scand. J. Immunol. 47, 159-162 (1998).
12. Sminia, T., van der Brugge Gamelkoorn, G.J. & Jeurissen, S.H. Structure and function of bronchus-associated lymphoid tissue (BALT). Crit. Rev. Immunol. 9, 119-150 (1989).
13. Pabst, R. & Gehrke, I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the king in normal mammals, including humans? Am. J. Respir. Cell Mol. Biol. 3, 131-135 (1990).
14. Tschernig, T. & Pabst, R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 68, 1-8 (2000).
15. Kocks, J.R., Davalos-Misslitz, A.C., Hintzen, G., Ohl, L. & Forster, R. Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue. J. Exp. Med. 204, 723-734 (2007).
16. Rangel-Moreno, J. et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J. Clin. Invest. 116, 3183-3194 (2006).
17. Das, A. et al. BALT development and augmentation of hyperoxic lung injury in mice deficient in NQO1 and NQO2. Free Radic. Biol. Med. 40, 1843-1856 (2006).
18. Moyron-Quiroz, J.E. et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25, 643-654 (2006).
19. Rangel-Moreno, J. et al. Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue. J. Immunol. 175, 4904-4913 (2005).
20. Wiley, J.A., Hogan, R.J., Woodland, D.L. & Harmsen, A.G. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J. Immunol. 167, 3293-3299 (2001).
21. Tamura, S. et al. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J. Gen. Virol. 79 (Pt 2), 291-299 (1998).
22. van der Brugge-Gamelkoorn, G.J., Claassen, E. & Sminia, T. Anti-TNP-forming cells in bronchus-associated lymphoid tissue (BALT) and paratracheal lymph node (PTLN) of the rat after intratracheal priming and boosting with TNP-KLH. Immunology 57, 405-409 (1986).
23. Suda, T., Sato, A., Sugiura, W. & Chida, K. Induction of MHC class II antigens on rat bronchial epithelial cells by interferon-gamma and its effect on antigen presentation. Lung 173, 127-137 (1995).
24. Hundorfean, G. et al. Luminal antigens access late endosomes of intestinal epithelial cells enriched in MHC I and MHC II molecules: in vivo study in Crohn's ileitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G798-G808 (2007).
25. Lawrence, C.W., Ream, R.M. & Braciale, T.J. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J. Immunol. 174, 5332-5340 (2005).
26. Kohlmeier, J.E. & Woodland, D.L. Memory T cell recruitment to the lung-airways. Curr. Opin. Immunol. 18, 357-362 (2006).
27. Puneet, P., Moochhala, S. & Bhatia, M. Chemokines in acute respiratory distress syndrome. Am. J. Physiol Lung Cell Mol. Physiol. 288 L3-L15 (2005).
28. D'Ambrosio, D., Mariani, M., Panina-Bordignon, P. & Sinigaglia, F. Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am. J. Respir. Crit. Care Med. 164, 1266-1275 (2001).
29. Hussell, T. & Openshaw, P.J.M. Intracellular interferon-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J. Gen. Virol. 79, 2593-2601 (1998).
30. Swain, S.L., Dutton, R.W. & Woodland, D.L. T cell responses to influenza virus infection: Effector and memory cells. Viral Immunol. 17 197-209 (2004).
31. Doherty, P.C. et al. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol. Rev. 159 105-117 (1997).
32. Humphreys, J. R. et al. A critical role for ICOS co-stimulation in immune containment of pulmonary influenza virus infection. Eur. J. Immunol. 36, 2928-2938 (2006).
33. Nakasone, C. et al. Accumulation of gamma/delta T cells in the lungs and their roles in neutrophil-mediated host defense against pneumococcal infection. Microbes. Infect. 9, 251-258 (2007).
34. Kirby, A.C., Newton, D.J., Carding, S.R. & Kaye, P.M. Evidence for the involvement of lung-specific gammadelta T cell subsets in local responses to Streptococcus pneumoniae infection. Eur. J. Immunol. 37, 3404-3413 (2007).
35. Huffnagle, G.B., Yates, J.L. & Lipscomb, M.F. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173, 793-800 (1991).
36. Humphreys, I.R. et al. OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J. Immunol. 170, 6125-6132 (2003).
37. Huffnagle, G.B., Boyd, M.B., Street, N.E. & Lipscomb, M.F. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160, 2393-2400 (1998).
38. Murphy, J., Summer, R., Wilson, A.A., Kotton, D.N. & Fine, A. The prolonged life-span of alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 38, 380-385 (2008).
39. Holt, P.G. et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J. Exp. Med. 177, 397-407 (1993).
40. Hussell, T., Spender, L.C., Georgiou, A., O'Garra, A. & Openshaw, P.J.M. Th1 and Th2 cytokine induction in pulmonary T-cells during infection with respiratory syncytial virus. J. Gen. Virol. 77, 2447-2455 (1996).
41. Brandtzaeg, P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25, 5467-5484 (2007).
42. Wines, B.D. & Hogarth, P.M. IgA receptors in health and disease. Tissue Antigens 68, 103-114 (2006).
43. Holt, P.G., Strickland, D.H., Wilkstrom, M.E. & Jahnsen, F.L. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8, 142-152 (2008).
44. Bilyk, N. & Holt, P.G. Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 177, 1773-1777 (1993).
45. Eriksson, U. et al. Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. J. Immunol. 175 2715-2720 (2005).
46. Mayer, A.K. et al. Differential recognition of TLR-dependent microbial ligands in human bronchial epithelial cells. J. Immunol. 178, 3134-3142 (2007).
47. Pichavant, M. et al. Impact of bronchial epithelium on dendritic cell migration and function: Modulation by the bacterial motif KpOmpA. J. Immunol. 177, 5912-5919 (2006).
48. Cox, G., Gauldie, J. & Jordana, M. Bronchial epithelial cell-derived cytokines (G-CSF and GM-CSF) promote the survival of peripheral blood neutrophils in vitro. Am. J. Respir. Cell Mol. Biol. 7, 507-513 (1992).
49. Bleck, B., Tse, D.B., Jaspers, I., Curotto de Lafaille, M.A. & Reibman, J. Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation. J. Immunol. 176, 7431-7437 (2006).
50. Raz, E. Organ-specific regulation of innate immunity. Nat. Immunol. 8, 3-4 (2007).
51. Takabayshi, K. et al. Induction of a homeostatic circuit in lung tissue by microbial compounds. Immunity 24, 475-487 (2006).
52. Jakubzick, C., Tacke, F., Llodra, J., van Rooijen, N. & Randolph, G.J. Modulation of dendritic cell trafficking to and from the airways. J. Immunol. 176, 3578-3584 (2006).
53. Snelgrove, R.J., Edwards, L., Rae, A.J. & Hussell, T. An absence of reactive oxygen species improves the resolution of lung influenza infection. Eur. J. Immunol. 36, 1364-1373 (2006).
54. Williams, A.E. et al. TGF-beta prevents eosinophilic lung disease but impairs pathogen clearance. Microbes. Infect. 7, 365-374 (2005).
55. Bilyk, N. & Holt, P.G. Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage populations. Immunology 86, 231-237 (1995).
56. MacLean, J.A. et al. Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cell-mediated immunity. Am. J. Pathol. 148, 657-666 (1996).
57. Holt, P.G. Inhibitory activity of unstimulated alveolar macrophages on T-lymphocyte blastogenic response. Am. Rev. Respir. Dis. 118 791-793 (1978).
58. Lambrecht, B.N. Alveolar macrophage in the driver's seat. Immunity 24, 366-368 (2006).
59. Thepen, T., van Rooijen, N. & Kraal, G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J. Exp. Med. 170, 499-509 (1989).
60. Demedts, I.K., Brusselle, G.G., Vermaelen, K.Y. & Pauwels, R.A. Identification and characterization of human pulmonary dendritic cells. Am. J. Respir. Cell Mol. Biol. 32, 177-184 (2005).
61. Wikstrom, M.E. & Stumbles, P.A. Mouse respiratory tract dendritic cell subsets and the immunological fate of inhaled antigens. Immunol. Cell Biol. 85, 182-188 (2007).
62. Holt, P.G., Haining, S., Nelson, D.J. & Sedgwick, J.D. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways. J. Immunol. 153, 256-261 (1994).
63. Demedts, I.K., Bracke, K.R., Maes, T., Joos, G.F. & Brusselle, G.G. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am. J. Respir. Cell Mol. Biol. 35 387-393 (2006).
64. Schlecht, G. et al. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 104, 1808-1815 (2004).
65. Sapoznikov, A. et al. Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J. Exp. Med. 204, 1923-1933 (2007).
66. de Heer, H.J., Hammad, H., Kool, M. & Lambrecht, B.N. Dendritic cell subsets and immune regulation in the lung. Semin. Immunol. 17 295-303 (2005).
67. Hammad, H. & Lambrecht, B.N. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J. Allergy Clin. Immunol. 118, 331-336 (2006).
68. Lambrecht, B.N. Dendritic cells and the regulation of the allergic immune response. Allergy 60, 271-282 (2005).
69. Grayson, M.H. & Holtzman, M.J. Emerging role of dendritic cells in respiratory viral infection. J. Mol. Med. 85, 1057-1068 (2007).
70. Smit, J.J., Rudd, B.D. & Lukacs, N.W. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J. Exp. Med. 203, 1153-1159 (2006).
71. Wang, H., Peters, N. & Schwarze, J. Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. J. Immunol. 177, 6263-6270 (2006).
72. Hammad, H. & Lambrecht, B.N. Lung dendritic cell migration. Adv. Immunol. 93, 265-278 (2007).
73. Barclay, A.N., Wright, G.J., Brooke, G. & Brown, M.H. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 23, 285-290 (2002).
74. Osterholzer, J.J. et al. CCR2 and CCR6, but not endothelial selectins, mediate the accumulation of immature dendritic cells within the lungs of mice in response to particulate antigen. J. Immunol. 175, 874-883 (2005).
75. Robays, L.J. et al. Chemokine receptor CCR2 but not CCR5 or CCR6 mediates the increase in pulmonary dendritic cells during allergic airway inflammation. J. Immunol. 178, 5305-5311 (2007).
76. Vermaelen, K.Y., Carro-Muino, I., Lambrecht, B.N. & Pauwels, R.A. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. Med. 193, 51-60 (2001).
77. Sung, S.S. et al. A major lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins. J. Immunol. 176, 2161-2172 (2006).
78. Hogan, R.J. et al. Long-term maintenance of virus-specific effector memory CD8+ T cells in the lung airways depends on proliferation. J. Immunol. 169, 4976-4981 (2002).
79. Harris, N.L., Watt, V., Ronchese, F. & Le Gros, G. Differential T cell function and fate in lymph node and nonlymphoid tissues. J. Exp. Med. 195, 317-326 (2002).
80. Ely, K.H., Cookenham, T., Roberts, A.D. & Woodland, D.L. Memory T cell populations in the lung airways are maintained by continual recruitment. J. Immunol. 176, 537-543 (2006).
81. Peper, R.L. & Van Campen, H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb. Pathog. 19 175-183 (1995).
82. Kurokawa, M., Imakita, M., Kumeda, C.A. & Shiraki, K. Cascade of fever production in mice infected with influenza virus. J. Med. Virol. 50, 152-158 (1996).
83. Kozak, W., Conn, C.A., Kir, J.J., Wong, G.H. & Kluger, M.J. TNF soluble receptor and antiserum against TNF enhance lipopolysaccharide fever in mice. Am. J. Physiol 269, R23-R29 (1995).
84. Kozak, W. et al. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am. J. Physiol 272, R621-R630 (1997).
85. Cook, D.N. The role of MIP-1 alpha in inflammation and hematopoiesis. J. Leukoc. Biol. 59, 61-66 (1996).
86. Rutigliano, J.A. & Graham, B.S. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infecton. J. Immunol. 173, 3408-3417 (2004).
87. Sedgwick, J.B., Menon, I., Gem, J.E. & Busse, W.W. Effects of inflammatory cytokines on the permeability of human lung microvascular endothelial cell monolayers and differential aosinophil transmigration. J Allergy Clin. Immunol. 110, 752-756 (2002).
88. Mazzon, E. & Cuzzocrea, S. Role of TNF-alpha in lung tight junction alteration in mouse model of acute lung inflammation. Respir. Res. 8, 75 (2007).
89. Watts, TH. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005).
90. Bansal-Pakala, P., Halteman, B.S., Cheng, M.H. & Croft, M. Costimulation of CD8 T cell responses by OX40. J. Immunol. 172, 4821-4825 (2004).
91. Ito, T. et al. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. USA 103, 13138-13143 (2006).
92. Serghides, L. et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: Comparison with B7.1 and 4-1 BBL. J. Immunol. 175, 6368-6377 (2005).
93. Zubairi, S., Sanos, S.L., Hill, S. & Kaye, P.M. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania. donovani. Eur. J. Immunol. 34, 1433-1440 (2004).
94. Munks, M.W., Mourich, D.V., Mittler, R.S., Weinberg, A.D. & Hill, A.B. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 112, 559-566 (2004).
95. Humphreys, I.R. et al. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J. Exp. Med. 198 1237-1242 (2003).
96. Hendriks, J. et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175, 1665-1676 (2005).
97. Dawicki, W., Bertram, E.M., Sharpe, A.H. & Watts, T.H. 4-1 BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J. Immunol. 173, 5944-5951 (2004).
98. Vidric, M., Suh, W.K., Dianzani, U., Mak, T.W. & Wafts, T.H. Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice. J. Immunol. 175, 7288-7296 (2005).
99. Zaini, J. et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J. Clin. Invest 117 3330-3338 (2007).
100. Lane, P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J. Exp. Med. 191, 201-206 (2000).
101. Kotani, A., Hori, T., Matsumura, Y. & Uchiyama, T. Signaling of gp34 (OX40 ligand) induces vascular endotheliall cells to produce a CC chemokine RANTES/CCL5. Immunol. Lett. 84, 1-7 (2002).
102. Sugamura, K., Ishii, N. & Weinberg, A.D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev. Immunol. 4, 420-431 (2004).
103. Bertram, E.M., Lau, P. & Watts, T.H. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J. Immunol. 168, 3777-3785 (2002).
104. Lumsden, J.M., Roberts, J.M., Harris, N.L., Peach, R.J. & Ronchese, F. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection. J. Immunol. 164, 79-85 (2000).
105. Pietrella, D. et al. Disruption of CD40/CD40L interaction influences the course of Cryptococcus neoformans infection. FEMS Immunol. Med. Microbiol. 40, 63-70 (2004).
106. Hendriks, J., Xiao, Y. & Borst, J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector Y cell pool. J. Exp. Med. 198, 1369-1380 (2003).
107. Behnia, M., Robertson, K.A. & Martin, W.J. Lung infections: Role of apoptosis in host defense and pathogenesis of disease. Chest 117, 1771-1777 (2000).
108. Lasbury, M.E. et al. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J. Immunol. 176, 6443-6453 (2006).
109. Gramme, H. et al. CD95/OD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 290 527-530 (2000).
110. Richter, M.V. & Topham, D.J. The alpha 1 beta 1 integrin and TNF receptor 11 protect airway CD8+ effector T cells from apoptosis during influenza infection. J. Immunol. 179, 5054-6063 (2007).
111. Zhou, J., Matsuoka, M., Cantor, H., Homer, R. & Enelow, R.I. Cutting edge: Engagement of NKG2A on CD8+ effector T cells limits immunopathology in influenza pneumonia. J. Immunol. 180, 25-29 (2008).
112. Uliprasertkul, M. et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg. Infect. Dis. 13, 708-712 (2007).
113. Lam, W.Y. et al. Avian influenza A/HK/483/97(H5N1) NS1 protein induces apoptosis in human airway epithelial cells. J. Virol. 82, 2741-2751 (2008).
114. Tumpey, T.M., Lu, X., Morken, T, Zaki, S.R. & Katz, J.M. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N 1) virus isolated from humans. J. Virol. 74, 6105-6116 (2000).
115. Sieg, S., King, C., Huang, Y. & Kaplan, D. The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3. J. Virol. 70, 4845-4848 (1996).
116. Fan, T. et al. Inhibition of apoptosis in chlamydia-infected cells: Blockade of mitochondrial cytochrome c release and caspase activation. J. Exp. Med. 187, 487-496 (1998).
117. Hakansson, A. et al. Aspects on the interaction of Streptococcus pneumoniae and Haemophilus influenzae with human respiratory tract mucosa. Am. J. Respir Crit. Care Med. 154, S187-S191 (1996).
118. Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689 (2007).
119. Butcher, E.C. & Picker, L.J. Lymphocyte homing and homeostasis. Science 272, 60-66 (1996).
120. Stuve, O. & Bennett, J.L. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 13, 79-95 (2007).
121. Dedrick, R.L., Walicke, P. & Garovoy, M. Anti-adhesion antibodies efalizumab, a humanized anti-CD1 1a monoclonal antibody. Transpl. Immunol. 9, 181-186 (2002).
122. Li, Y.Y., Perez, H.D. & Zollner, T.M. Fatalities in natalizumab treatment - a'no go' for leukocyte recirculation approaches? Expert Opin. Ther. Targets 10, 489-499 (2006).
123. Glass, W.G., Rosenberg, H.F. & Murphy, P.M. Chemokine regulation of inflammation during acute viral infection. Curr. Opin. Allergy Clin. Immunol. 3, 467-473 (2003).
124. Charo, I.F. & Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
125. Proudfoot, A.E., Power, C.A., Rommel, C. & Wells, T.N. Strategies for chemokine antagonists as therapeutics. Semin. Immunol 15, 57-65 (2003).
126. Moser, B. Chemokines: Role in immune cell traffic. Eur. Cytokine Netw. 14 204-210 (2003).
127. Kinashi, T. Intracellular signalling controlling integrin activation in lymphocytes. Nat. Rev. Immunol. 5, 546-559 (2005).
128. Devalaraja, M.N. & Richmond, A. Multiple chemotactic factors: Fine control or redundancy? Trends Pharmacol. Sci. 20, 151-156 (1999).
129. Sakai, S. et al. Therapeutic effect of anti-macrophage inflammatory protein 2 antibody on influenza virus-induced pneumonia in mice. J. Virol. 74, 2472-2476 (2000).
130. Brundage, J.F. Interactions between influenza and bacterial respiratory pathogens: Implications for pandemic preparedness. Lancet Infect Dis. 6, 303-312 (2006).
131. Beading, C. & Slifka, M. K. How do viral infections predispose patients to bacterial Infections? Curr. Opin. Infect Dis. 17, 185-191, (2004).
132. Schall, T.J., Bacon, K., Toy, K.J. & Goeddel, D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature (London) 347, 669-671 (1990).
133. Proudfoot, A.E. et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271, 2599-2603 (1996).
134. Culley, F.J. et al. Role of CCL5 (RANTES) in viral lung disease. J. Virol. 80, 8151-8157 (2006).
135. Rosenberg, H.F., Bonville, C.A., Easton, A.J. & Domachowske, J.B. The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: Identifying novel targets for therapeutic intervention. Pharmacol. Ther. 105, 1-6 (2005).
136. Amano, H. et al. Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia. J. Immunol. 172 398-409 (2004).
137. Zeng, X. et al. Interferon-inducible protein 10, but not monokine induced by gamma interferon, promotes protective type 1 immunity in murine Klebsiella pneumoniae pneumonia. Infect. Immun. 73, 8226-8236 (2005).
138. Culley, F.J., Pennycook, A.M., Tregoning, J.S., Hussell, T. & Openshaw, P.J. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J. Virol. 80, 4521-4527 (2006).
139. Lee, B.J. et al. Role of CXCR3 in the immune response to murine gammaherpesvirus 68. J. Virol. 79, 9351-9355 (2005).
140. Bonville, C.A. et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol. 78, 7984-7989 (2004).
141. John, A.E. et al. Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCR1-associated immune responses. Eur. J. Immunol. 35, 108-116 (2005).
142. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (London) 427, 355-360 (2004).
143. Jacobson, J.R. & Garcia, J.G. Novel therapies for microvascular permeability in sepsis. Curr. Drug Targets 8, 509-514 (2007).
144. Rodriguez-Monroy, M.A., Rojas-Hernandez, S. & Moreno-Fierros, L. Phenotypic and functional differences between lymphocytes from NALT and nasal passages of mice. Scand. J. Immunol. 65, 276-288 (2007).
145. Racedo, S. et al. Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Microbes. Infect. 8, 2359-2366 (2006).
146. Selin, L.K. et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol. Rev. 211 164-181 (2006).
147. Kamradt, T., Goggel, R. & Erb, K.J. Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol. 26, 260-267 (2005).
148. Walzi, G., Tafuro, S., Moss, P., Openshaw, P.J. & Hussell, T. Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. J. Exp. Med. 192, 1317-1326 (2000).
149. Chen, H. D. et al. Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung. Nat. Immunol. 2, 1067-1076 (2001).
150. Chen, H.D., Fraire, A.E., Joris, I., Welsh, R.M. & Selin, L.K. Specific history of heterologous virus infections determines antiviral immunity and immunopathology in the lung. Am. J. Pathol. 163, 1341-1355 (2003).
151. Walzi, G. et al. Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner. Infect. Immun. 71, 3384-3391 (2003).
152. Didierlaurent, A. et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J. Exp. Med. 205, 323-329 (2008).
153. Edwards, L. et al. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur. J. Immunol. 35, 273-281 (2005).
154. Williams, A.E. et al. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J. Immunol. 173, 7435-7443 (2004).
155. Maizels, R.M. Infections and allergy - helminths, hygiene and host immune regulation. Curr. Opin. Immunol. 17, 656-661 (2005).
156. Furze, R.C., Hussell, T. & Selkirk, M.E. Amelioration of influenza-induced pathology in mice by coinfection with Trichinella spiralis. Infect. Immun. 74, 1924-1932 (2006).
157. Williams, A.E., Edwards, L. & Hussell, T. Colonic bacterial infection abrogates eosinophilic pulmonary disease. J. Infect. Dis. 193 223-230 (2006).
158. Lu, C.C., Lai, H.C., Hsieh, S.C. & Chen, J.K. Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats. J. Leukoc. Biol. 83, 1028-1037 (2008).
159. Ohta, Y. et al. In vivo anti-influenza virus activity of an immunomodulatory acidic polysaccharide isolated from Cordyceps militaris grown on germinated soybeans. J. Agric. Food Chem. 55, 10194-10199 (2007).
160. Yamada, H., Mizuno, S., Ross, A.C. & Sugawara, I. Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with Mycobacterium tuberculosis. J. Nutr. 137, 2696-2700 (2007).
161. Liew, F.Y. & Cox, F.E. Nonspecific defence mechanism: The role of nitric oxide. Immunol. Today 12, A17-A21 (1991).
162. Nagata, M. Inflammatory cells and oxygen radicals. Curr. Drug Targets Inflamm. Allergy 4, 503-504 (2005).
163. Jean, D. et al. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit. Care Med. 30, 442-447 (2002).
164. Ader, F. et al. Inhaled nitric oxide increases endothelial permeability in Pseudomonas aeruginosa pneumonia. Intensive Care Med. 33, 503-510 (2007).
165. Sun, Z., Sun, B., Wang, X., Wang, W. & Zhu, L. Anti-inflammatory effects of inhaled nitric oxide are optimized at lower oxygen concentration in experimental Klebsiella preumoniae pneumonia. Inflamm. Res. 65 430-440 (2006).
166. Stark, J.M. et al. Immune and functional role of nitric oxide in a mouse model of respiratory syncytial virus infection. J. Infect. Dis. 191, 387-395 (2005).
167. Castro, S.M. et al. Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation. Am. J. Respir. Crit. Care Med. 174, 1361-1369 (2006).
168. Sidwell, R.W. et al. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice. Antimicrob. Agents Chemother. 40, 2626-2631 (1996).
169. Davis, I.C. et al. Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection. Am. J. Respir. Cell Mol. Biol. 37, 379-386 (2007).
170. Brown, K.L., Cosseau, C., Gardy, J.L. & Hancock, R.E. Complexities of targeting innate immunity to treat infection. Trends Immunol. 28, 260-266 (2007).
171. Park, G.Y. & Christman, J.W. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr. Drug Targets 7, 661-668 (2006).
172. O'Neill, L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5, 549-563 (2006).
173. Lee, M.S. & Kim, Y.J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 76, 447-480 (2007).
174. Bernasconi, D., Amici, C., La Frazia, S., Ianaro, A. & Santoro, M.G. The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells. J. Biol. Chem. 280, 24127-24134 (2005).
175. Haeberle, H.A. et al. IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection. J. Virol. 78, 2232-2241 (2004).
176. Sadikot, R.T. et al. Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J. Immunol. 176, 4923-4930 (2006).
177. Cheng, D.S. et al. Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J. Immunol. 178, 6504-6513 (2007).
178. Everhart, M.B. et al. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J. Immunol. 176, 4995-5005 (2006).
179. Zingarelli, B. & Cook, J.A. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23, 393-399 (2005).
180. Michalik, L. & Wahli, W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Invest. 116, 598-606 (2006).
181. Arnold, R., Neumann, M. & Konig, W. Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology 121, 71-81 (2007).
182. Ashwell, J.D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 6, 532-540 (2006).
183. Singh, D., McCann, K.L. & Imani, F. MAPK and heat shock protein 27 activation are associated with respiratory syncytial virus induction of human bronchial epithelial monolayer disruption. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L436-L445 (2007).
184. Garcia, J.G. et al. Critical involvement of p38 MAP kinase in pertussis toxin-induced cytoskeletal reorganization and lung permeability. FASEB J. 16, 1064-1076 (2002).
185. Duan, W. et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 171, 571-578 (2005).
186. Kehrl, J.H. Chemoattractant receptor signaling and the control of lymphocyte migration. Immunol. Res. 34, 211-227 (2006).
187. Thomas, M.J. et al. Airway inflammation: Chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur. J. Immunol. 35, 1283-1291 (2005).
188. Pinho, V. et al. Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. J. Immunol. 179, 7891-7898 (2007).
189. Boonans, C., Fukunaga, K., Keledjian, R., Petasis N.A. & Levy, B.D. Regulation of phosphatidylinositol-3-kinase by polyisoprenyl phosphates
190. Myou, S. et al. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J. Exp. Med. 198, 1573-1582 (2003).
191. Maus, U.A. et al. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am. J. Respir. Crit. Care Med. 175, 958-966 (2007).
192. Kumagai, Y. et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 27, 240-252 (2007).
193. Barnard, D.L. et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 17, 275-284 (2006).
194. Guerrero-Plata, A. et al. Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J. Virol. 79, 10190-10199 (2005).
195. Haagmans, B.L. et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10, 290-293 (2004).
196. Yoon, H.J., Zhu, Z., Gwaltney, J.M. Jr & Elias, J.A. Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro: a potential mechanism of symptom resolution. J. Immunol. 162 7461-7469 (1999).
197. Rijneveld, A.W. et al. Interleukin-1 receptor antagonist transiently impairs antibacterial defense but not survival in murine pneumococcal pneumonia. Eur. Cytokine Netw. 14, 242-245 (2003).
198. Kostense, S. et al. Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice. Antiviral Res. 38, 117-130 (1998).
199. Hussell, T., Khan, U. & Openshaw, P.J.M. IL-12 treatment attenuates Th2 and B cell responses but does not improve vaccine-enhanced lung illness. J. Immunol. 159, 328-334 (1997).
200. Cain, J.A. & Deepe, G.S. Jr Interleukin-12 neutralization alters lung inflammation and leukocyte expression of CD80, CD86, and major histocompatibility complex class II in mice infected with Histoplasma capsulatum. Infect. Immun. 68, 2069-2076 (2000).
201. Brieland, J.K., Remick, D.G., LeGendre, M.L., Engleberg, N.C. & Fantone, J.C. In vivo regulation of replicative Legionella pneumophila lung infection by endogenous interleukin-12. Infect. Immun. 66, 65-69 (1998).
202. Hussell, T., Pennycook, A. & Openshaw, P.J. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31, 2566-2573 (2001).
203. Kirby, A.C., Raynes, J.G. & Kaye, P.M. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae. J. Infect. Dis. 191, 1538-1547 (2005).
204. Herring, A.C. et al. Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: Potential role of immature dendritic cells. Infect. Immun. 73, 39-49 (2005).
205. Piessner, H.L. et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J. Infect. Dis. 195, 1643-1650 (2007).
206. Salomon, R., Hoffmann, E. & Webster, R.G. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Natl. Acad. Sci. USA 104, 12479-12481 (2007).
207. Baumgarth, N. & Kelso, A. In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J. Virol. 70, 4411-4418 (1996).
208. Sarawar, S.R., Sangster, M., Coffman, R.L. & Doherty, P.C. Administration of anti-IFN-gamma antibody to b2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J. Immunol. 153, 1246-1253 (1994).
209. Nakamatsu, M. et al. Role of interferon-gamma in Valpha14+ natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes. Infect. 9, 364-374 (2007).
210. Wu, Q. et al. IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection. Microbes. Infect. 9, 78-86 (2007).
211. Happel, K.I. et al. Cutting edge: Roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170, 4432-4436 (2003).
212. Greenberger, M.J. et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 155, 722-729 (1995).
213. van der Sluijs, K.F. et al. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J. Infect. Dis. 193, 214-222 (2006).
214. Ramilo, O. et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109, 2066-2077 (2007).
215. Heritage, P.L., Underdown, B.J., Arsenault, A.L., Snider, D.P. & McDermott, M.R. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 156, 1256-1262 (1997).
216. Asanuma, H. et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods 202, 123-131 (1997).
217. Blair, C., Naclerio, R.M., Yu, X., Thompson, K. & Sperling, A. Role of type 1 T helper cells in the resolution of acute Streptococcus pneumoniae sinusitis: A mouse model. J. Infect. Dis. 192, 1237-1244 (2005).